Concizumab (zita rekutengesa, Alhemo), monoclonal antibody yakabvumidzwa neFDA musi wa20 Zvita 2024 kudzivirira kubuda ropa muvarwere vane hemophilia A ine factor VIII inhibitors kana hemophilia B ine factor IX inhibitors. Yakanga yawana mvumo neEuropean Medicines Agency (EMA) mazuva mashoma apfuura musi wa16 Zvita 2024 kune zvimwe chete zviratidzo.
Vamwe varwere vane haemophilia vari pa "clotting factor medication" yekurapa chirwere chavo chekubuda ropa vanogadzira masoja ekudzivirira chirwere (anopesana nemishonga inogwamba). Masoja ekudzivirira chirwere anogadzirwa anotadzisa kuita kwe "clotting factor medicine" zvichiita kuti isashande. Ichi chirwere parizvino chiri kurapwa nekukurudzira kushivirira kwemuviri kuburikidza nemajekiseni emazuva ese ekuvhara zvinhu. Kubvumidzwa kweConcizumab (Alhemo) kunopa varwere vakadaro kumwe kurapwa.
Concizumab inopihwa zuva nezuva se subcutaneous jekiseni.
Kubvumirwa kweAlhemo kwakabva pakuongororwa kwekuchengetedzwa kwayo uye kubudirira mune imwe nyika yakawanda, yakawanda-kati, yakazaruka-label, chikamu 3 kliniki yekuedza. Mukutongwa, kuwanda kwekubuda ropa kwegore negore (ABR) kwakaderedzwa ne86% yeboka rekurapa reAlhemo richienzaniswa neboka risina prophylaxis.
Matambudziko ekubuda ropa muhemophilia anokonzerwa nekusakwana kwezvinhu zvinogwamba. Hemophilia A inokonzerwa nekushaikwa kwe clotting factor VIII, ukuwo haemophilia B ichikonzerwa nekudzikira kwefactor IX. Kushaikwa kwechigadzirwa chekushanda XI chinokonzera haemophilia C. Mamiriro aya anorapwa nekupinza chinhu chakagadzirwa nekutengesa kana chimwe chinhu chisingaiti sechinhu chinoshanda chekutsiva chinhu chisipo.
Octocog alfa (Advate), inova 'yakagadzirwa nemagetsi uchishandisa DNA tekinoroji' ye clotting factor VIII, inowanzoshandiswa kudzivirira pamwe chete nevanoda kurapwa kwehemophilia A. Pahemophilia B, nonacog alfa (BeneFix), iyo is an engineered version ye clotting factor IX inowanzoshandiswa.
Hympavzi (marstacimab-hncq), munhu monoclonal antibody akanangana ne "tissue factor pathway inhibitor" nguva pfupi yadarika yakabvumidzwa semushonga mutsva wekudzivirira kubuda ropa muvanhu vane hemophilia A kana hemophilia B.
***
References:
- FDA inobvumidza mushonga wekudzivirira kana kuderedza kuwanda kwekubuda ropa kuvarwere vane hemophilia A ine inhibitors kana hemophilia B ine inhibitors. Yakatumirwa 20 Zvita 2024. Inowanikwa pa https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or
- EMA. Alhemo – Concizumab. Available https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo uye https://ec.europa.eu/health/documents/community-register/html/h1881.htm
- NHS. Kurapa Hemophilia. Inowanikwa pa https://www.nhs.uk/conditions/haemophilia/treatment/
- CDC. Kurapa Hemophilia. Inowanikwa pa https://www.cdc.gov/hemophilia/treatment/index.html
Chinyorwa chinoenderana
- Hympavzi (marstacimab): Kurapwa Kutsva kweHemophilia. Scientific European. Yakatumirwa 12 Gumiguru 2024. Inowanikwa pa https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
***
